Citations

Clear

3942 citation(s) found for "To, Van".

Type IV Hereditary Sensory and Autonomic Neuropathy: Challenges and Functional Outcomes
Dudic, Ahmed, Schuyver, Paul Van , Tassel, Dane Van , Belthur, Mohan V. , Van Schuyver, Paul

Mayo Clinic

Journal of Pediatric Orthopaedics | August 18, 2025 | Volume: 46 | Issue: 3 | Pages: e282-e287

10.1097/bpo.0000000000003084 | PMID 40824224 Get It

Background: Type IV Hereditary Sensory and Autonomic Neuropathy (HSAN IV) is an exceedingly rare autosomal recessive disease classically characterized by generalized loss of temperature/pain sensation, intellectual disability, and anhidrosis. HSAN IV patients are subject to repeated orthopaedic injuries and complications. There is some data on the clinical presentation, but limited data on the diagnostic and treatment challenges, and functional outcomes with HSAN IV. Methods: This is a retrospective case series of 4 siblings with HSAN IV. Medical records were reviewed for data regarding presentation, diagnosis, and management. Functional outcomes were assessed using the Pediatric Outcomes Data Collection Instrument, with historical normative data used as a control. The 2 populations were evaluated with a Welch-modified 2-sample t test to explore the alternative hypothesis that HSAN IV patients are significantly functionally impaired. Results: Our study included 4 siblings, 2 males and 2 females, aged 3, 8, 12, and 21 years, respectively. The average time to diagnosis was 53 months, and each diagnosis was confirmed through whole-exome sequencing. The challenges faced included delayed diagnosis, diverse clinical presentations, unestablished treatment guidelines, and unnecessary healthcare utilization before definitive diagnosis. The comparison of means between the normative population and the HSAN IV patients revealed a significant difference in sports/play ( T -score =−4.14, P =0.025) and global function ( T -score =−3.19, P =0.049) but no significant difference in upper extremity function ( P =0.216), transfer mobility ( P =0.164), pain/comfort ( P =0.955), and happiness ( P =0.995). Conclusions: HSAN IV is a rare genetic condition with protean clinical manifestations that can result in significant deficits in play and global function. The clinical manifestations are varied, including multiple fractures, delayed/abnormal fracture healing, bone deformity, osteomyelitis, and various other non-orthopaedic manifestations. Whole-exome sequencing is a useful tool that, when combined with a high index of clinical suspicion, can expedite the diagnostic process for HSAN IV. Patients can benefit from earlier diagnosis and earlier access to education to prevent functional deterioration and repeat medical interventions. Level of Evidence: IV—case series.
Defining Treatment‐Resistant Bipolar Depression: Recommendations From the ISBD Task Force
Vieta, Eduard , McIntyre, Roger S. , Suppes, Trisha , Singh, Balwinder , Miskowiak, Kamilla Woznica , Young, Allan H. , Berk, Michael , Henry, Chantal, Cubała, Wiesław Jerzy , Tohen, Mauricio , Post, Robert M. , Bauer, Michael , Fradera, Xavier Justes, Cosials-Lopez, Montserrat, Singh, Balwinder , Berk, Michael , Swartz, Holly A , Diaz, Gerard Anmella , Hidalgo-Mazzei, Diego , Tohen, Mauricio , Pacchiarotti, Isabella , Nunes, Paula Villela , Post, Robert , Fico, Giovanna , Vieta, E , McIntyre, Roger S , Cubała, Wiesław J , Young, Allan H , Van Rheenen, Tamsyn , Yatham, Lakshmi N. , Ha, Kyooseob , Swartz, Holly A. , Henry, Chantal , Pantović-Stefanović, Maja , Anmella, Gerard , Özerdem, Ayşegül , López‐Jaramillo, Carlos , González‐Pinto, Ana , Brambilla, Paolo , Soares, Jair C. , Andreazza, Ana C. , Fico, Giovanna

Mayo Clinic

Bipolar Disorders | August 14, 2025 | Volume: 27 | Issue: 6 | Pages: 411-423

10.1111/bdi.70048 | PMID 40808269 Get It

ABSTRACT Objective Despite the availability of approved treatments, a substantial proportion of patients with bipolar disorder experience treatment‐resistant bipolar depression (TRBD), characterized by persistent depressive symptoms unresponsive to standard therapies. However, a universally accepted definition of TRBD is lacking. This consensus document, developed by the International Society for Bipolar Disorders (ISBD) Task Force on TRBD, aims to provide a standardized definition of TRBD to facilitate clinical trials, research, and treatment strategies. Methods The Task Force employed a literature review, clinical trials analysis, and expert consensus meetings to define TRBD. Results TRBD was defined as the failure to achieve a significant and sustained clinical response after at least two approved and adequately dosed pharmacological treatments, administered for a sufficient duration with treatment adherence. For bipolar I (BD‐I) depression, approved treatments included quetiapine (300–600 mg/day for ≥ 8 weeks), lurasidone (20–120 mg/day for ≥ 6 weeks), the combination of olanzapine (6–12 mg/day) and fluoxetine (25–75 mg/day for ≥ 8 weeks), cariprazine (1.5–3 mg/day for ≥ 6 weeks), and lumateperone (42 mg/day for ≥ 6 weeks). For bipolar II (BD‐II) depression, approved treatments included quetiapine (300–600 mg/day for ≥ 8 weeks) and lumateperone (42 mg/day for ≥ 6 weeks). Conclusion This consensus definition aims to provide clarity for clinical trials, improve consistency in research, and guide treatment approaches and inform regulatory pathways. It represents a foundational step in addressing the unmet needs in TRBD and promoting the development of innovative therapeutic strategies. Future efforts will focus on adapting the definition to better align with real‐world clinical challenges and optimize patient care.
Body mass index and subsequent fracture risk: a meta-analysis to update FRAX
Harvey, Nicholas C. , Johansson, Helena, McCloskey, Eugène , Liu, Enwu , Åkesson, Kristina , Anderson, Fred, Bager, Cecilie L. , Christiansen, Claus, Cooper, Cyrus , Crandall, Carolyn , Cummings, Steven R. , Dawson‐Hughes, Bess , Eisman, John A. , Fujita, Yuki , Fujiwara, Saeko , Glüer, Claus‐Christian , Guðnason, Vilmundur , Hall, Jill, Huisman, Martijn , Iki, Masayuki , Ish‐Shalom, Sophia, Koromani, Fjorda , Kröger, Heikki , Esfahani, Zahra , McGuigan, Fiona E. , Mellström, Dan, Merlijn, Thomas , Nguyen, Tuan V., Ohlsson, Claes , Pasco, Julie A. , Rivadeneira, Fernando, Schei, Berit , Shiroma, Eric J. , Siggeirsdóttir, Kristín , Swart, Karin M. A. , Tamaki, Junko , Staa, Tjeerd van , Wareham, Nicholas J, Yoshimura, Noriko , Zwart, Marta , Kanis, John A, McCloskey, Eugene V , Åkesson, Kristina E , Biver, Emmanuel , Center, Jacqueline R , Cooper, Cyrus , Crandall, Carolyn J , Dawson-Hughes, Bess , Dufour, Alyssa B , Eisman, John A , Ferrari, Serge , Hans, Didier B. , Iki, Masayuki , Karlsson, Magnus K , Khosla, Sundeep , Kiel, Douglas P , Koromani, Fjorda , Kwok, Timothy , Lamy, Olivier , Larijani, Bagher , McGuigan, Fiona E A , Merlijn, Thomas , Ohlsson, Claes , Orwoll, Eric S , Simonsick, Eleanor Marie , Sund, Reijo , Szulc, Pawel , Tamaki, Junko , Wright, Nicole C , Zillikens, M. Carola , Lorentzon, Mattias , Leslie, William D , Azagra, Rafael , Beaudart, Charlotte , Bischoff‐Ferrari, Heike A. , Biver, Emmanuel , Bruyère, Olivier , Cauley, Jane A. , Chapurlat, Roland D , Silva, José António Pereira da , Díez‐Pérez, Adolfo , Elders, Petra J. M. , Ferrari, Serge , Goldshtein, Inbal , Goltzman, David , Hall, Jill, Hoff, Mari , Hollick, Rosemary J , Jones, Graeme , Khosla, Sundeep , Kiel, Douglas P. , Koh, Woon‐Puay , Kotowicz, Mark A. , Langhammer, Arnulf , Lippuner, Kurt , Nordström, Anna , Nordström, Peter , O’Neill, Terence W , Obermayer-Pietsch, Barbara Maria , Orwoll, Eric , Rivadeneira, Fernando , Schott, Anne‐Marie , Sornay‐Rendu, Elisabeth , Szulc, Paweł , Torgerson, David John , Schoor, Natasja M. van , Vila, Joan , Vandenput, Liesbeth , Lorentzon, Mattias , Leslie, William D. , Kanis, John A.

Mayo Clinic

Journal of Bone and Mineral Research | August 12, 2025 | Volume: 40 | Issue: 10 | Pages: 1144-1155

10.1093/jbmr/zjaf091 | PMID 40795319 Get It

Abstract The aim of this international meta-analysis was to quantify the predictive value of BMI for incident fracture and relationship of this risk with age, sex, follow-up time, and BMD. A total of 1 667 922 men and women from 32 countries (63 cohorts), followed for a total of 16.0 million person-years were studied. 293 325 had FN BMD measured (2.2 million person-years follow-up). An extended Poisson model in each cohort was used to investigate relationships between WHO-defined BMI categories (Underweight: <18.5 kg/m2; Normal: 18.5-24.9 kg/m2; Overweight: 25.0-29.9 kg/m2; Obese I: 30.0-34.9 kg/m2; Obese II: ≥35.0 kg/m2) and risk of incident osteoporotic, major osteoporotic and hip fracture (HF). Inverse-variance weighted β-coefficients were used to merge the cohort-specific results. For the subset with BMD available, in models adjusted for age and follow-up time, the hazard ratio (95% CI) for HF comparing underweight with normal weight was 2.35 (2.10-2.60) in women and for men was 2.45 (1.90-3.17). Hip fracture risk was lower in overweight and obese categories compared to normal weight [obese II vs normal: women 0.66 (0.55-0.80); men 0.91 (0.66-1.26)]. Further adjustment for FN BMD T-score attenuated the increased risk associated with underweight [underweight vs normal: women 1.69 (1.47-1.96); men 1.46 (1.00-2.13)]. In these models, the protective effects of overweight and obesity were attenuated, and in both sexes, the direction of association reversed to higher fracture risk in Obese II category [Obese II vs Normal: women 1.24 (0.97-1.58); men 1.70 (1.06-2.75)]. Results were similar for other fracture outcomes. Underweight is a risk factor for fracture in both men and women regardless of adjustment for BMD. However, while overweight/obesity appeared protective in base models, they became risk factors after additional adjustment for FN BMD, particularly in the Obese II category. This effect in the highest BMI categories was of greater magnitude in men than women. These results will inform the second iteration of FRAX®.
Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease
Bruin, Hannah de , Groot, Colin , Barthel, Henryk , Bischof, Gérard N. , Boon, Baayla D.C. , Brendel, Matthias , Cash, David M. , Coath, William , Day, Gregory S. , Dyck, Christopher H. van , Fredericks, Carolyn , Fryer, Tim D. , Graff‐Radford, Jonathan , Hobbs, Diana A. , Hoenig, Merle C. , Josephs, Keith A. , Katsumi, Yuta , Joie, Renaud La , Xiong, Chengjie , Malpetti, Maura , McGinnis, Scott M., Mecca, Adam P. , O’Brien, John T. , Putcha, Deepti , Rabinovici, Gil D. , Rahmouni, Nesrine , Rullmann, Michael , Saur, Dorothee , Servaes, Stijn , Sintini, Irene , Stevenson, Jenna , Stomrud, Erik , Strandberg, Olof, Tideman, Pontus , Touroutoglou, Alexandra , Trainer, Anne, Wekselman, Fattin, Weston, Philip S.J. , Whitwell, Jennifer L. , Yong, Keir , de Bruin, Hannah , Brendel, Matthias , Cash, David M , Coath, William , Dickerson, Bradford Clark , van Eimeren, Thilo , van der Flier, Wiesje M , Fredericks, Carolyn A , Gordon, Brian A , Graff-Radford, Jonathan , Grinberg, Lea , Hansson, Oskar , Irwin, David J , Josephs, Keith A , Katsumi, Yuta , La Joie, Renaud , Lee, Edward B , Xiong, Chengjie , Malpetti, Maura , Mohanty, Rosaleena , O'Brien, John Tiernan , Palleis, Carla , Phillips, Jeffrey S , Putcha, Deepti , Rosa-Neto, Pedro , Schott, Jonathan M , Schroeter, Matthias L , Smith, Ruben , Spina, Salvatore , Therriault, Joseph , Whitwell, Jennifer , Yong, Keir X X , Franzmeier, Nicolai , Day, Gregory S , Stomrud, Erik , Rabinovici, Gil D , Blazhenets, Ganna , Boellaard, Ronald , Doering, Elena , Drzezga, Alexander E. , Flier, Wiesje M. van der , Giessen, Elsmarieke van de , Gordon, Brian A. , Grinberg, Lea T. , Hansson, Oskar , Höglinger, Günter U. , Irwin, David J. , Jones, Peter Simon , Lee, Edward B. , Mohanty, Rosaleena , Nasrallah, Ilya M. , O’Dell, Ryan S. , Perneczky, Robert , Rowe, James B. , Sabri, Osama , Schildan, Andreas , Schott, Jonathan M. , Seeley, William W. , Servaes, Stijn , Spina, Salvatore , Visser, Denise , Wolk, David A. , Pijnenburg, Yolande A.L. , Franzmeier, Nicolai , Ossenkoppele, Rik

Mayo Clinic

Brain | August 8, 2025 | Volume: 148 | Issue: 11 | Pages: 3893-3912

10.1093/brain/awaf279 | PMID 40810361 Get It

Abstract The link between regional tau load and clinical manifestation of Alzheimer’s disease (AD) highlights the importance of characterizing spatial tau distribution across disease variants. In typical (memory-predominant) AD, the spatial progression of tau pathology mirrors the functional connections from temporal lobe epicentres. However, given the limited spatial heterogeneity of tau in typical AD, atypical (non-amnestic-predominant) AD variants with distinct tau patterns provide a key opportunity to investigate the universality of connectivity as a scaffold for tau progression. In this large-scale, multicentre study across 14 international sites, we included cross-sectional tau-PET data from 320 individuals with atypical AD (n = 139 posterior cortical atrophy/PCA-AD; n = 103 logopenic variant primary progressive aphasia/lvPPA-AD; n = 35 behavioural variant AD/bvAD; n = 43 corticobasal syndrome/CBS-AD), with a subset of individuals (n = 78) having longitudinal tau-PET data. Additionally, as an independent sample, we included regional post-mortem tau stainings from 93 atypical AD patients from two sites (n = 19 PCA-AD, n = 32 lvPPA-AD, n = 23 bvAD, n = 19 CBS-AD). Gaussian mixture modelling was used to harmonize different tau-PET tracers by transforming tau-PET standardized uptake value ratios to tau positivity probabilities (a uniform scale ranging from 0% to 100%). Using linear regression, we assessed whether brain regions with stronger resting-state functional MRI-based functional connectivity, derived from healthy elderly controls in the Alzheimer’s Disease Neuroimaging Initiative (ADNI), showed greater covariance in cross-sectional and longitudinal tau-PET and post-mortem tau pathology. Furthermore, we examined whether functional connectivity of tau-PET epicentres (i.e. the top 5% of regions with the highest baseline tau load) and tau-PET accumulation epicentres (i.e. the top 5% of regions with the highest tau accumulation rates) was associated with cross-sectional and longitudinal tau patterns. Our findings show that tau-PET epicentres aligned with clinical variants, e.g. a visual network predominant pattern in PCA-AD (‘visual AD’) and left-hemispheric temporal predominance, particularly within the language network, in lvPPA-AD (‘language AD’). Moreover, more strongly functionally connected regions showed correlated concurrent tau-PET levels (confirmed with post-mortem data) and tau-PET accumulation rates. The functional connectivity profile of tau-PET epicentres and accumulation epicentres corresponded to tau-PET progression patterns, with higher tau-PET levels and accumulation rates in functionally close regions, and lower tau-PET levels and accumulation rates in functionally distant regions. Our data are consistent with the hypothesis that tau propagation occurs along functional connections originating from local epicentres, across all AD clinical variants. Since tau proteinopathy is a major driver of neurodegeneration and cognitive decline, this finding may advance personalized medicine and participant-specific end points in clinical trials.
Rethinking psychological treatment targets for pediatric rumination syndrome: Clinical implications from a case series analysis
Anastasiadis, William A. , Gloe, Lilianne M. , Johnson-Kwochka, Annalee V. , Diest, Ashley M. Kroon Van , Lagges, Ann, Wagoner, Scott T. , Williams, Amy E. , Sparks, Brandon , Gilbert, Elaine

Mayo Clinic

JPGN Reports | August 7, 2025 | Volume: 6 | Issue: 4 | Pages: 382-386

10.1002/jpr3.70074 | PMID 41245029 Get It

Abstract Rumination syndrome (RS) is a common pediatric disorder of gut–brain interaction. However, a dearth of research on efficacious treatment to help guide clinical decision‐making remains. Thus, relying on well‐established treatment recommendations for other conditions with similar mechanisms or symptom profiles may be helpful; for example, conceptualizing RS treatment targets to address it as a “tic disorder of the gut” could be beneficial. To demonstrate the clinical utility of this conceptualization, we presented two cases that provide broad implications for treating pediatric RS. In both cases, akin to pediatric tic and related disorders, cognitive distress and physical discomfort were alleviated temporarily by rumination episodes. Thus, we recommend a targeted diagnostic assessment, including a functional analysis incorporating a transdiagnostic evaluation of symptoms. Close comanagement with specialty physicians and psychologists is also highly recommended. The patients represent complex yet standard cases seen in pediatric psychology outpatient clinics, suggesting the clinical utility of implications for psychologists and allied health professionals.
Treatment and outcomes of progression of disease post–CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis
Epstein‐Peterson, Zachary D. , Lionel, Anath C. , Joseph, Ashlee , Drill, Esther , Atallah‐Yunes, Suheil Albert , Brooks, Taylor , Chong, Elise A. , Chong, Emeline R. , Cruz, Jamie Dela , Frank, Matthew J. , Jacobson, Caron A. , Beyar‐Katz, Ofrat , Maddocks, Kami J. , McLoughlin, Daniel E. , Navalekar, Rohin, Ryan, Christine E. , Sauter, Craig S. , Sharma, Samanvaya , Shukla, Navika , Therwhanger, Dylan , Besien, Herman J. van, Varon, Ben , Yamshon, Samuel , Palomba, M. Lia , Kumar, Anita , Brooks, Taylor R , Kamdar, Manali , Karmali, Reem , Matasar, Matthew , McLoughlin, Daniel , Rhodes, Joanna , Riedell, Peter A , Ryan, Christine E , Salles, Gilles A , Sawalha, Yazeed , Sharma, Samanvaya , Shouval, Roni , Therwhanger, Dylan , van Besien, Herman , Varon, Ben , Wang, Yucai , Yamshon, Samuel , Zelenetz, Andrew D , Jain, Preetesh , Kumar, Anita , Chong, Elise A , Joseph, Ashlee , Atallah-Yunes, Albert , Ip, Andrew , Iqbal, Madiha , Kamdar, Manali , Karmali, Reem , Matasar, Matthew J. , Merryman, Reid W. , Muñoz, Javier , Navalekar, Rohini, Rhodes, Joanna , Riedell, Peter A. , Salles, Gilles , Sawalha, Yazeed , Wang, Yucai , Zelenetz, Andrew D. , Jain, Preetesh

Mayo Clinic

Blood Advances | August 5, 2025 | Volume: 9 | Issue: 21 | Pages: 5654-5662

10.1182/bloodadvances.2025016315 | PMID 40763269 Get It

Abstract The treatment patterns and clinical outcomes for patients experiencing progression of disease (POD) following CD19-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) mantle cell lymphoma (MCL) are undefined. We identified all patients who received CD19-directed CAR T-cell therapy for R/R MCL therapy across 15 international centers, and studied those experiencing POD post–CAR T-cell therapy in detail. We extracted clinical/treatment/pathologic variables, and associated these features with survival outcomes. In total, 384 patients received CAR T-cell therapy, and 135 (35%) experienced POD. POD occurred at a median of 6 months following CAR T-cell therapy infusion, and most (64%) patients with POD had complete response as best response to CAR T-cell therapy. Tumor features at POD included blastoid/pleomorphic morphology in 29 of 78 (37%) patients, and TP53 mutation in 21 of 41 (51%) patients. Following POD, 17 patients received no further therapy, 13 underwent local therapy, and 105 received systemic therapy. The most common first-line systemic therapies were chemo(immuno)therapy (22 patients; overall response rate [ORR], 40%), pirtobrutinib (17 patients; ORR, 36%), and bispecific antibodies (13 patients; ORR, 67%). Among patients experiencing POD, the median progression-free survival and overall survival (OS) were 2.5 months and 5.4 months, respectively, from POD. Lack of response to CAR T-cell therapy and short time from CAR T-cell therapy infusion to POD (<3 vs 3-6 vs >6 months), among other factors, were associated with inferior OS after POD. In conclusion, we confirm the challenging prognosis for patients experiencing POD following CD19 CAR T-cell therapy for R/R MCL, and establish a benchmark for future investigations in this patient population.
The role of radiotherapy in MPNST and the impact of NF1 status on outcomes: Insights from a multicenter cohort study
Jansma, Christianne Y. M. N. , Grünhagen, Dirk J. , Flucke, Uta , Slooff, Willem‐Bart M., Dalen, Thijs van , Been, Lukas B. , Bonenkamp, Han J. , Anten, Monique , Broen, Martinus P. G. , Bemelmans, Marc H.A., Bramer, Jos A. M. , Schaap, Gerard R. , Hage, Jos A. van der , Pendleton, Courtney , Spinner, Robert J. , Erasmus, Coert Frederik , Taal, Walter , Martin, Enrico , Coert, J Henk , Verhoef, Cornelis , Taal, Walter , Grünhagen, Dirk J , Kievit, Arthur J. , Houdt, Winan J. van , Sande, Michiel A. J. van de , Coert, J. Henk , Verhoef, Cornelis

Mayo Clinic

Neuro-Oncology | August 5, 2025 | Volume: 27 | Issue: 12 | Pages: 3214-3223

10.1093/neuonc/noaf186 | PMID 40795877 Get It

Abstract Background Malignant peripheral nerve sheath tumors (MPNSTs) are rare, aggressive sarcomas, with 40% associated with neurofibromatosis type 1 (NF1). Surgical excision is the main treatment for localized disease; however, local recurrence (LR) remains high. Radiotherapy (RTx) is increasingly used to enhance local control in STS, but its use remains controversial due to the potential for increased major wound complications and an increased risk of secondary malignancies in NF1 patients. This study investigated the use and impact of RTx on local control in MPNSTs, particularly in the NF1 setting. Methods Surgically treated primary MPNSTs from 1988 to 2019 in the MONACO multicenter cohort were included. Differences in demographics, treatment, and RTx use between NF1 and non-NF1 cases were examined. Factors influencing RTx administration and LR were assessed via multivariable analyses. Results Among 499 patients (33.1% NF1), 143 (28.7%) experienced LRs. Radiotherapy was administered to 56.3% of patients (57.0% in the NF1 group), with 27.3% receiving neoadjuvant and 72.7% adjuvant RTx. RTx was administered significantly more often to high-grade and extremity tumors. While RTx did not affect overall survival, it reduced LR risk in sporadic cases (hazard ratio [HR] 0.530; 95% confidence interval [CI], 0.354–0.793) but not in the NF1 subgroup (HR 1.00; 95% CI, 0.545–1.85). In NF1 patients, a microscopically positive margin (R1) was the only risk factor for LR development (HR 2.1; 95% CI, 1.19–3.79). Conclusions RTx is frequently used in the treatment of MPNSTs, regardless of NF1 status. While it may affect the LR rate in sporadic cases, its impact on NF1 patients is less clear.
Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia‐specific perspectives
Carrillo, Marı́a C., Chen, Christopher , Choi, Seong Hye , Fontana, Igor C. , Graff‐Radford, Jonathan, Heidebrink, Judith L. , Hu, Chaur‐Jong , Ihara, Ryoko , Ip, Fanny C.F., Fitri, Fasihah Irfani , Jack, Clifford R. , Yoon, Soo Jin , Jia, Jianping , Kandiah, Nagaendran, Kowa, Hisatomo , Joie, Renaud La , Noritake, Ryoji, Okonkwo, Ozioma C. , Raman, Rema , Shen, Yong , Simuni, Tanya, Snyder, Heather M. , Sriwannopas, Orapitchaya, Wang, Huali , Zhou, Jin , Sexton, Claire E. , Carrillo, María C. , Simuni, Tanya , Chen, Christopher , Mahinrad, Simin , Jack, Clifford R , La Joie, Renaud , Simuni, Tanya , Iwatsubo, Takeshi , Sperling, Reisa Anne , Algeciras‐Schimnich, Alicia , Arai, Hidenori , Barron, Anna M. , Benzinger, Tammie L.S. , Graff‐Radford, Jonathan , Grill, Joshua D. , Ikeuchi, Takeshi , Iwata, Atsushi , Kandiah, Nagaendran , Kim, SangYun , Niimi, Yoshiki , Palmqvist, Sebastian , Rafii, Michael S. , Stoeckel, Luke E. , Flier, Wiesje M. van der , Wilcock, Donna M. , Zetterberg, Henrik , Mahinrad, Simin

Mayo Clinic

Alzheimer's & Dementia | August 5, 2025 | Volume: 21 | Issue: 8 | Pages: No page available

10.1002/alz.70536 | PMID 40760693 Get It

Abstract The landscape of Alzheimer's disease (AD) and related dementias (ADRD) diagnosis is evolving rapidly, driven by advances in disease understanding, biomarker tools, and disease‐modifying therapies. Modern diagnostic approaches emphasize biological precision, early detection, and dynamic frameworks that adapt to treatment‐induced changes in disease biology. These frameworks enable opportunities for personalized interventions—encompassing pharmacological and non‐pharmacological strategies—and for enhanced clinical trial design. However, implementing these advancements globally is influenced by diverse cultural, infrastructural, and regulatory factors. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis, held in Japan, provided a unique platform to explore these global dynamics, particularly from an Asian perspective. This article highlights key discussions from the conference, exploring the role of biomarker‐based diagnostic frameworks in shaping the future of AD/ADRD research, diagnosis, and treatment. We highlight regional challenges and successes and emphasize ethical considerations and practical strategies needed to ensure equitable access to diagnostic and therapeutic innovations. Highlights Advances in biomarkers are reshaping Alzheimer's disease diagnosis and treatment. Modern diagnostic frameworks highlight biological precision, early detection, and dynamic frameworks. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis explored challenges and opportunities in global biomarker implementation. The conference explored geographic‐specific impacts, focusing on Asia.
The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Glandular Lesions of the Urinary Bladder
Paner, Gladell P. , Cunha, Isabela W. , Amin, Mahul B. , Aron, Manju , Athanazio, Daniel Abensur , Bambury, Richard , Cheng, Liang, Gopalan, Anuradha , Gulmann, Christian, Harris, Carole A. , Jiménez, Rafael E. , Jinzaki, Masahiro , Lal, Priti , Miyai, Kosuke , Netto, George J. , Pan, Chin-Chen, Rhijn, Bas W. van, Smith, Steven C. , Wobker, Sara E. , Reis, Henning , Lesions, ISUP Expert Panel On Urachal Neoplasms and Urinary Bladder Glandular, Cheng, Liang , Cheng, Liang , Al-Ahmadie, Hikmat A , Gaisa, Nadine Therese , López-Beltrán, Antonio , Maclean, Fiona M. , Tsuzuki, Toyonori , Aning, Jonathan J. , Guo, Charles Chuanhai , Iyer, Gopa , Kikuchi, Eiji , Pan, Chin‐Chen , Panebianco, Valeria , Siefker-Radtke, Arlene Odelia , Szarvas, Tibor , Kristiansen, Glen , Lesions, ISUP Expert Panel On Urachal Neoplasms and Urinary Bladder Glandular

Mayo Clinic

Advances in Anatomic Pathology | August 4, 2025 | Volume: 33 | Issue: 1 | Pages: 1-16

10.1097/pap.0000000000000510 | PMID 40757456 Get It

The Dublin ISUP Consensus Conference covered the proceedings on the best practice recommendations on nonurachal glandular lesions of the urinary bladder, bladder diverticular cancers, and molecular features of bladder and urachal glandular lesions. The conference proceedings on urachal neoplasms (except for their molecular features) are published elsewhere. The rationale for convening this conference was the lack of structured and consented pathologic recommendations in these rare lesions. Consensus by participants was reached on the following statements: (1) intestinal metaplasia with dysplasia is considered to be a precursor to primary bladder adenocarcinoma; (2) dysplasia arising from cystitis glandularis should be reported in terms of focality (focal or nonfocal) and grade (low or high); (3) the term “adenocarcinoma” should only be used for carcinomas showing pure (nonurothelial) morphology and should not be used interchangeably in urothelial carcinoma with “glandular differentiation” because of the pathobiological differences and management implications; (4) the different histologic subtypes of bladder adenocarcinoma should be specified in the report; (5) immunohistochemistry has an ancillary role in the work up of bladder adenocarcinoma versus gastrointestinal or Müllerian-type adenocarcinomas; (6) lymphovascular invasion should be included as a parameter when reporting bladder adenocarcinoma; (7) representative or targeted sampling will be sufficient for bladder diverticulum resection specimens; and (8) molecular analysis in genomic profiling should be performed only in advanced or metastatic bladder and urachal adenocarcinomas for targetable therapy. This report on glandular (nonurachal) lesions of the bladder from the Dublin ISUP consensus conference will serve as a best practice recommendation and as a guide for future research on these relatively rare lesions.